Premier Biomedical, Inc.
Other OTCTotal Valuation
Premier Biomedical, Inc. carries a market capitalization of 899,983.00, placing it among publicly traded companies globally.
| Market Cap | 899,983.00 |
| Enterprise Value | N/A |
Share Statistics
Premier Biomedical, Inc. currently has 262.11M shares outstanding.
| Shares Outstanding | 262.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.41, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.41 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | -0.02 |
| P/OCF Ratio | -0.02 |
Financial Position
Premier Biomedical, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.05 |
| Quick Ratio | 0.04 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -0.83 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -281.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -3.73 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.66 |
Stock Price Statistics
Premier Biomedical, Inc.'s stock has gained approximately 50% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 50% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Premier Biomedical, Inc. generated 14,281.00 in revenue and converted that into -374,470.00 in net income, yielding earnings per share of -0.03. EBITDA reached -323,905.00, while operating income came in at -326,735.00.
| Revenue | 14,281.00 |
| Gross Profit | 1,421.00 |
| Operating Income | -326,735.00 |
| Pretax Income | -374,470.00 |
| Net Income | -374,470.00 |
| EBITDA | -323,905.00 |
| EBIT | -326,735.00 |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
Total book value stands at -17.10M, with working capital of -1.84M providing operational flexibility.
| Cash & Cash Equivalents | 71,197.00 |
| Total Debt | N/A |
| Net Debt | 89,551.00 |
| Equity (Book Value) | -17.10M |
| Book Value Per Share | -1.16 |
| Working Capital | -1.84M |
Cash Flow
Premier Biomedical, Inc. produced -344,180.00 in operating cash flow over the past twelve months. After subtracting -4,850.00 in capital expenditures, free cash flow totaled -349,030.00 - equivalent to -0.02 per share.
| Operating Cash Flow | -344,180.00 |
| Capital Expenditures | -4,850.00 |
| Free Cash Flow | -349,030.00 |
| FCF Per Share | -0.02 |
Margins
Premier Biomedical, Inc. operates with a gross margin of 9.95, reflecting its pricing power and cost economics. The operating margin of -2,287.90 and net profit margin of -2,622.16 provide insight into operational efficiency.
| Gross Margin | 9.95 |
| Operating Margin | -2,287.90 |
| Pretax Margin | -2,622.16 |
| Profit Margin | -2,622.16 |
| EBITDA Margin | -2,268.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5,644.67 |
| FCF Yield | -5,745.07 |
Stock Splits
Premier Biomedical, Inc.'s most recent stock split took place on June 27, 2018 with a 250:1 split ratio.
| Last Split Date | 6/27/2018 |
| Split Ratio | 250:1 |
Scores
Premier Biomedical, Inc. posts an Altman Z-Score of -269.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -269.61 |